Back to search results

ANCILE-30: C7R.CD30-CAR-EBVSTs for CD30 Lymphoma

This study, called ANCILE-30, is testing a new cell therapy called C7R.CD30-CAR-EBVSTs for people aged 16 to 75 with certain types of lymphoma that have come back or are not responding to treatment. These include Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-cell Lymphoma (PTCL), and Anaplastic Large Cell Lymphoma. The treatment uses your own immune cells (Epstein-Barr virus-specific T lymphocytes) that are specially modified to find and fight cancer cells with a marker called CD30. The main goal of this study is to see how safe this new treatment is. Researchers will also look at how well the treatment works against the cancer and how the modified cells behave in your body. The study plans to enroll 21 participants, and its current status is unclear.

Study design
This is a Phase I interventional study designed to evaluate the safety of the C7R.CD30-CAR-EBVSTs treatment. It plans to enroll 21 participants.
What's involved
You would first have your blood cells collected to create the treatment. If the treatment is successfully made and you still meet the criteria, you would receive chemotherapy followed by an infusion of the C7R.CD30-CAR-EBVSTs.
Compensation
Not stated in the trial record.
Follow-up
The primary safety outcomes are measured from the start of chemotherapy through 28 days after the initial cell infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07729397

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

Not Yet Recruiting
PHASE1Ages 16–75InterventionalTreatment
The Methodist Hospital Research Institute
~21 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:Autologous C7R.CD30-CAR-EBVSTs

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Dose-Limiting Toxicities (DLTs)
Measured over From initiation of lymphodepleting chemotherapy through 28 days following the initial investigational T-cell infusion.

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)
Hodgkin Lymphoma
Peripheral T-cell Lymphoma (PTCL)
Anaplastic Large Cell Lymphoma, ALK-Positive
Anaplastic Large Cell Lymphoma, ALK-Negative

Explore related trials

Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveDiffuse Large B-Cell LymphomaHodgkin's GranulomaMature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Helen Heslop, MD · PRINCIPAL_INVESTIGATOR · The Methodist Hospital Research Institute
  • Premal Lulla, MD · PRINCIPAL_INVESTIGATOR · The Methodist Hospital Research Institute

Who to contact

Premal Lulla, MD
[email protected]
713-441-1450
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Hodgkin lymphoma
CD30+ aggressive B-cell lymphoma
ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma
ALK-positive anaplastic T cell lymphoma 2. CD30 expression confirmed in a CLIA-certified laboratory. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy 3. Age 16 to 75 years. 4. Bilirubin ≤ 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin ≤ 3 times the upper limit of normal). 5. AST ˂ 3 times the upper limit of normal 6. Estimated GFR \> 50 mL/min 7. Pulse oximetry of \> 90% on room air 8. Karnofsky or Lansky score of \> 60% 9. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after study is concluded. Male partner should use a condom 10. Informed consent explained to, understood by and signed by patient/guardian. Patient/Guardian given copy of informed consent.

What this trial measures

  • Incidence of Dose-Limiting Toxicities (DLTs)From initiation of lymphodepleting chemotherapy through 28 days following the initial investigational T-cell infusion.

    Dose-limiting toxicity (DLT) is defined as any of the following considered possibly, probably, or definitely related to study cellular products: (1) Grade 5 event without disease progression; (2) CRS: Grade 4, or Grade 3 not improving to ≤Grade 2 within 72 hours despite therapy; (3) ICANS: Grade 4, or Grade 3 not improving within 72 hours despite therapy; (4) Grade ≥3 IEC-HS; (5) Grade 4 neutropenia or thrombocytopenia not attributable to underlying disease or lymphodepleting chemotherapy and not improving to ≤Grade 2 within 42 days, or Grade 3 thrombocytopenia with clinically significant major bleeding; (6) Grade ≥3 vital organ toxicity (except transient hepatic or renal abnormalities improving to ≤Grade 2 within 7 days); (7) other Grade 3 toxicities not attributable to underlying disease or lymphodepleting chemotherapy and not resolving to ≤Grade 2 within 72 hours; (8) Grade ≥2 allergic reaction to T-cell infusion.